Disclosure(s): No relevant financial relationship(s) to disclose.
Disclosure(s):
Nadir Yehya, MD, MSCE: No relevant financial relationship(s) to disclose.
The detection of soluble biomarkers has the potential to have a much shorter analysis time. Sepsis induces the production of many biomarkers, and upward of 250 individual biomarkers have already been studied with varying success in clinical roles. While no single biomarker has been proven to be a specific indicator of sepsis, rapid detection of key biomarkers could provide useful diagnostic and prognostic values. This presentation will highlight the importance of rapid detection, the specific biomarkers that are more accurate and cost effective, late-breaking research on newer biomarkers being studied such as Angiopoietins, Endocans, Ludkocyte surface antigens, and genomic regulators of sepsis that may identify illness way before the feared “genomic storm!" The presenter will explain the varying, unique sensors needed to identify these biomarkersincluding and which is cost effective for your ICU. Biomarkers in sepsis offers reduced reliance on PCR and blood culture tests which may lower operational costs and expand availability. Ultimately, the most important benefit is the potential for early diagnosis that leads to timely and successful treatment with improved patient outcomes.
